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INTRODUCTION
Pre-eclampsia (PE) is a pregnancy-related disorder, characterized by the onset of hypertension and proteinuria after 20 weeks of gestation 1 , which constitutes a major cause of maternal and fetal morbidity and mortality 2, 3 . Although the pathophysiology of PE is not understood fully, it is well established that the placenta plays a central role in development of the disease. It has been hypothesized that genetic, immunologic and environmental factors lead to poor placentation, which leads to the imbalanced production of pro-and anti-angiogenic biomarkers [4] [5] [6] . As a result, women with PE have been shown to have decreased serum concentrations of placental growth factor (PlGF) and increased levels of soluble fms-like tyrosine kinase-1 (sFlt-1) [7] [8] [9] . Therefore, sFlt-1/PlGF ratio has been evaluated for diagnosis of the disease and used to estimate the risk of imminent delivery [10] [11] [12] [13] [14] [15] [16] .
Women with PE experience cardiovascular alterations, such as increased blood pressure and peripheral vascular resistance, vasoconstriction or reduced plasma volume 17 . As these changes represent a stressful scenario, the heart responds by producing cardiac damage markers, which have been proposed as useful tools in the evaluation of PE [16] [17] [18] [19] . Moreover, PE is a risk factor for future cardiovascular disease 20, 21 . In particular, N-terminal pro-B natriuretic peptide (NT-proBNP), which is released from cardiac myocytes in response to myocardial stretch or ischemia and is used as a biomarker of chronic heart failure in non-obstetric populations 22 , is present at higher concentrations in women with PE [23] [24] [25] [26] [27] [28] . In pregnancies complicated by PE, there appears to be a graded increase in natriuretic peptide levels with increasing severity of the disease 24 , which may predict cardiovascular complications 29 . Additionally, the levels of NT-proBNP do not change throughout pregnancy in healthy women 30 , and its transplacental transfer seems negligible 31 . The rationale behind including NT-proBNP evaluation is the assessment of maternal consequences of PE, as NT-proBNP may reflect the cardiac changes occurring in the mother during PE.
The aim of this study was to develop a combination of biochemical markers for predicting short-term delivery in pregnancy with PE and a sFlt-1/PlGF ratio > 38, by assessing sFlt-1/PlGF ratio, NT-proBNP and the uric-acid Z-score.
METHODS

Study design
As shown by the PROGNOSIS (Prediction of Short-Term Outcome in Pregnant Women with Suspected Pre-eclampsia) study, a sFlt-1/PlGF ratio ≤ 38 adequately rules out the onset of PE in the subsequent week, before 37 weeks of gestation 16 . This finding is applicable to populations with varying incidence of PE and when the evaluated outcome is delivery as a result of PE, as assessed in our previous study 32 . We therefore conducted a longitudinal study to assess sFlt-1/PlGF ratio, NT-proBNP and uric acid Z-score only in patients with a sFlt-1/PlGF ratio > 38.
Subjects and samples
This was a prospective cohort study of pregnant women admitted to the obstetric emergency department or seen at the high-risk pregnancy clinic, with signs or symptoms of PE. A total of 495 women were enrolled at the Hospital Universitario Central de Asturias (HUCA) between January 2015 and June 2017. The inclusion criteria were: high blood pressure; proteinuria; worsening of pre-existing hypertension or proteinuria; abnormal uterine-artery Doppler; headache not responding to analgesics; visual symptoms (blurry vision or flashing lights) and/or severe edema affecting hands, feet or face; and a gestational age (GA) at arrival of 24 + 0 to 36 + 6 weeks. Abnormal uterine-artery Doppler was defined as pulsatility index above the 95 th percentile of the Spanish population 33 . Exclusion criteria were multiple pregnancy, samples obtained outside the range of 24 + 0 to 36 + 6 weeks, loss to follow-up and a sFlt-1/PlGF ratio ≤ 38. We adopted a repeated-measures design instead of using only baseline measurements, as the former allows for risk to be reassessed continually at each gestational week. Consequently, multiple measurements were performed for each patient, depending on whether or not clinical suspicion of PE persisted. We included only the first measurement for each gestational week.
As the severity of PE can vary greatly, its diagnosis was not established as an endpoint. Instead, we assessed severity of PE by considering the need for pregnancy termination as a result of PE. Therefore, the evaluated endpoint was diagnosis of PE leading to delivery within 1 week of the measurement.
Women who had manifest PE or a confirmed diagnosis of HELLP syndrome were not excluded, as this would reduce the external validity of the study. The majority of deliveries of women with PE were induced. The clinical staff making the decision to terminate pregnancy were blinded to the sFlt/PlGF ratio and NT-proBNP results. Laboratory staff members were blinded to subjects' clinical information. The study was approved by the Independent Ethics Committee of Asturias. Written informed consent was obtained from each patient.
Analytical assay
Blood samples were collected in serum separator tubes either at emergency admission or at the outpatient clinic, and centrifuged at 1200 g for 10 min. sFlt-1, PlGF and NT-proBNP concentrations were determined using an electrochemiluminescence immunoassay (Elecsys PlGF, sFlt-1 and NT-proBNP) on a Cobas e601 automated immunoanalyzer (Roche Diagnostics, Mannheim, Germany) with a turnaround time of 18 min. The measuring ranges were 3-10 000 pg/mL for PlGF, 10-85 000 pg/mL for sFlt-1 and 5-35 000 ng/mL for NT-proBNP, with corresponding limits of quantitation of 10 pg/mL, 15 pg/mL and 5 ng/mL, respectively. The interassay coefficients of variation, as determined with PreciControl Multimarker 1 and 2 for PlGF and sFlt-1, and with PreciControl Cardiac 1 and 2 (Roche Diagnostics) for NT-proBNP, ranged from 1.5% to 4.5% during the study. No specific interferences have been reported for any of the assays used. Elecsys sFlt-1, PlGF and NT-proBNP immunoassays were used in this study. Results may differ for other immunoassays.
Uric acid was measured using a colorimetric assay on the Cobas e501 immunoanalyzer (Roche Diagnostics). As uric acid level increases during non-hypertensive pregnancies, we adjusted it for GA and computed the uric acid Z-score 34 using the equation: (uric acid concentration − mean uric acid concentration for GA)/SD of uric acid concentration for GA.
Diagnostic criteria
Pre-eclampsia was diagnosed according to the American College of Obstetricians and Gynecologists (ACOG) definition 35 . Hypertension was defined as blood pressure ≥ 140/90 mmHg on two separate occasions (≥ 24 h apart). Proteinuria was defined as either ≥ 300 mg of protein per 24-h urine collection or a protein/creatinine ratio of ≥ 30 mg/mmol. Note that a score for protein of 2+ or greater on dipstick urinalysis and ≥ 30 mg of protein/dL in a spot urine sample was not considered a suitable marker of proteinuria. In the absence of proteinuria, PE was defined as new-onset hypertension with the new onset of any of the following: thrombocytopenia (< 100 000/μL), renal insufficiency (creatinine concentration > 1.1 mg/dL), impaired liver function, pulmonary edema, or cerebral or visual symptoms.
HELLP syndrome was defined as hemolysis (lactate dehydrogenase > 600 IU/L), elevated liver enzyme levels (aspartate aminotransferase > 70 IU/L) and low platelet count (< 100 000/μL) according to the Tennessee Classification System 36 . HELLP syndrome was considered a feature of severe PE. Nine (6.7%) pregnancies had diagnosis of HELLP syndrome.
Fetal growth restriction (FGR) was defined as estimated fetal weight below the 10 th percentile caused by a pathological process that inhibited the normal growth potential. This pathological process had to be demonstrated after 22 weeks of gestation with oligohydramnios (amniotic fluid index < 10 th percentile) or Doppler ultrasonography pulsatility index of the umbilical artery > 95 th percentile.
Final outcomes were reviewed by an independent obstetrician and were assessed at the time of delivery.
Statistical analysis
The aim of this study was the development of a short-term predictor of delivery in women with PE. As multiple marker measurements were taken for each subject at different timepoints, they are correlated. As such, the traditional regression model is inappropriate as it assumes independence among observations at different timepoints. If the correlation structure is not considered, there is high risk of false estimation of the regression model parameters 37 . Thus, Harrison and Hulin 38 recommended generalized estimating equations (GEEs) as an appropriate assessment tool for the analysis of longitudinal data. A GEE analysis was developed by Liang and Zeger 39, 40 and has been proven to provide more reliable regression estimation than traditional models for longitudinal data or repeated measures.
The GEE model, adjusted for patient clustering by gestational week at measurement, was used to determine the final set of covariates for inclusion in the model. The model estimated the risk of delivery with PE in the week following each measurement. GEE methodology was chosen because it is also capable of dealing appropriately with varying numbers of observations, so there is no need for balanced observations 39 . As the aim of this study was not about etiology but rather to assess the potential predictive ability of serum markers for delivery as a result of PE, we did not include patient features (maternal age, weight, comorbidities, etc) in the model. The Wald chi-square test was used to decide the inclusion of covariates in the GEE model, applying a backwards elimination process with P < 0.05. The gestational week of the measurement was retained to control for potential confounding effects. An exchangeable correlation structure was selected for GEE because it best described the correlation structure of the data among other correlation structures. This correlation structure indicates that each observation within an individual is correlated equally with every other observation in that individual 41 . The goodness-of-fit of the final model was then assessed using quasi-likelihood under the independence model criterion.
Comparisons between groups were performed using the Mann-Whitney U-test for quantitative variables and the chi-square test for proportions. Area under the receiver-operating characteristics (ROC) curve (AUC) estimates were calculated by bootstrapping, using 10 000
replicates.
The open-source, freely available R statistical software (R version 3.1.1) 42 was used to conduct all statistical analyses. GEE model construction and paired AUC comparisons were performed using the geepack 43 and pROC 44 R add-on packages, respectively.
RESULTS
Of the 495 enrolled women, 361 were excluded for multiple pregnancy (n = 22), samples obtained outside the range of 24 + 0 to 36 + 6 weeks (n = 174), loss to follow-up (n = 9) or a sFlt-1/PlGF ratio of 38 or below (n = 156) ( Figure 1 ). From each woman, only the first measurement for each gestational week was included (thus 112 samples were excluded). Ultimately, a total of 270 samples from 134 patients were analyzed. Of these women, 82 (61.2%) delivered as a result of PE, including 30 cases of early-onset PE (delivery before 34 weeks of gestation), 33 cases of late-onset PE with preterm birth (from 34 + 0 to 36 + 6 weeks) and 19 cases of late-onset PE with term birth (from 37 + 0 weeks onwards). In the latter group, seven women delivered after 38 weeks of gestation; they therefore did not meet the assessed endpoint (delivery with PE within 1 week from the measurement) when including samples taken at up to 37 weeks of gestation. Twenty-six (19.4%) women were diagnosed with PE after inclusion. Women were included at a median GA of 32.2 (interquartile range (IQR), 30.3-34.1) weeks and their pregnancy was prolonged for a median of 6 (IQR, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] days. Tables 1 and 2 show the epidemiological and clinical characteristics of the population and samples, respectively, according to study group.
Longitudinal assessment of effect of markers and GA on risk of delivery with PE over time GEE was performed to ascertain the effect of the sFlt-1/PlGF ratio, NT-proBNP and uric-acid Z-score on the likelihood of delivery with PE within 1 week, with consideration for the gestational week in which From the y-value provided by the model, the patient-specific a-posteriori risk (π) for delivery with PE within 1 week is given by the formula: π = e y /(1 + e y ). This model is referred to as the combined model.
Another GEE model was constructed, based solely on the log-transformed sFlt-1/PlGF ratio and GA at the time of the measurement. Its estimated equation is:
This model is referred to as the reduced model. According to the corrected quasi-likelihood under the independence model criterion (QICC), the combined model was found to be better than the reduced model as the QICC of the former is 235.3, which is lower than that of the reduced model (266.0).
As both models were estimated from the same population, we also compared the predictive ability of the two models from the respective ROC curves (Figure 2 ). The estimate of the AUC of the combined model was 0.845 (95% CI, 0.787-0.896), which was significantly greater (DeLong test P = 0.011) than the estimate of the AUC of the reduced model, which was 0.786 (95% CI, 0.722-0.844). Data are given as median (interquartile range) or %. *P < 0.05 for comparison with women without PE. †There may have been more than one reason for suspected pre-eclampsia. ‡Majority of symptoms were feet edema. BMI, body mass index; BP, blood pressure; CH, chronic hypertension; FGR, fetal growth restriction; GA, gestational age. As the study design was longitudinal and the risk of presenting delivery with PE increased with GA, a fixed cut-off of sFlt-1/PlGF ratio and NT-proBNP could not be set. However, for the optimal cut-off of the ROC curve (which maximizes the Youden index) of the combined model, the sensitivity and false-positive rate (FPR) were 73.6% and 14.1%, respectively. For the same sensitivity, the FPR of the reduced model increased to 32.3%. This means that, by adding NT-proBNP, a FPR reduction that is 18.2% greater than that using different cut-offs of the sFlt-1/PlGF ratio could be achieved.
Complementary analysis
We also performed post-hoc retrospective analyses considering only one measurement per patient in order to assess the behavior of predictors in different situations.
NT-proBNP as a short-term marker
In pregnancies delivered without development of PE (n = 52), NT-proBNP did not vary throughout the pregnancy (median = 38; IQR, 25-67). Spearman's correlation coefficient for the relationship between NT-proBNP and GA at first determination was not significantly different from 0 (r, -0.135; P = 0.35) ( Figure S1 ).
Longitudinal assessment of sFlt-1/PlGF ratio and NT-proBNP was performed considering delivery as the reference point. During the last 2 weeks of pregnancy, sFlt-1/PlGF ratio and NT-proBNP were both significantly higher in pregnancies presenting PE at delivery compared with those not affected. When considering samples obtained before 2 weeks of delivery, this difference was also significant for sFlt-1/PlGF ratio but not for NT-proBNP (Figures 3 and 4) . This finding indicates that NT-proBNP increases in pregnancy with PE that is close to delivery.
In order to ensure that maternal features did not alter NT-proBNP level, NT-proBNP distributions were compared between pregnancies with and those without diverse dichotomic factors (gestational diabetes, chronic hypertension, parity, PE in previous pregnancy, in-vitro fertilization, FGR, obesity, maternal age > 40 years), considering only pregnancies without PE. We also assessed the correlation between NT-proBNP and the continuous factors body mass index and maternal age on pregnancies that did not deliver as a result of PE. All performed tests gave a non-significant result (Table S1 and Figures S2 and S3) . Race, renal disease and previous diabetes were not assessed because there were no Afro-Caribbean subjects or patients with nephropathy, and only two patients with pre-existing diabetes.
Isolated FGR
A total of 34 (25.4%) out of 134 pregnancies did not exhibit isolated FGR or PE at delivery, 18 (13.4%) presented isolated FGR and 82 (61.2%) experienced PE with or without FGR. Considering only the last measurement for each pregnancy, predictors were compared between the three groups. Median sFlt-1/PlGF ratio was 58 (IQR, 44-79) for normal pregnancies, 143 (IQR, 58-321) for the isolated FGR group and 174.5 (IQR, 97-457) for the PE group. Median NT-proBNP was 47.5 (IQR, 25-89) for normal pregnancies, 48 (IQR, 24-59) for the isolated FGR group and 156.5 (IQR, 78-343) for the PE group. There were significant differences in the sFlt-1/PlGF ratio between normal pregnancies and the isolated FGR group, and between normal pregnancies and the PE group, but not between the isolated FGR and PE groups (P = 0.14). Conversely, there were significant differences in NT-proBNP between normal pregnancies and the PE group, and between the isolated FGR and PE groups, but not between normal pregnancies and the isolated FGR group (P = 0.56) ( Figure 5 ).
Chronic hypertension
A total of 11 (8.2%) pregnancies were affected by chronic hypertension, of whom seven delivered as a result of PE before 38 weeks of gestation.
Considering only the last included measurement, we did not detect any significant variation in NT-proBNP at first determination between pregnancies without hypertension (n = 40; median = 35; IQR, 24.5-62.5), pregnancy-induced hypertension (n = 10; median = 60.5; IQR, 36-92), and chronic hypertension without PE (n = 2; median = 30.5; IQR, [28] [29] [30] [31] [32] [33] . However, these results may be biased because of the small number of samples available in these subgroups. Box-and-whisker plots of soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio (a) and N-terminal pro-B natriuretic peptide (NT-proBNP) concentration (b) (both on logarithmic scale) in pregnancies with pre-eclampsia (PE) that delivered prematurely ( ) and those which did not ( ), grouped according to number of weeks before delivery that measurement was taken. Only one measurement per week for each patient was considered. Isolated fetal growth restricted pregnancies were excluded. Boxes represent median and interquartile range (IQR) and whiskers represent 1.5 × IQR. sFlt-1/PlGF ratio cut-off of 38 is shown ( ). Asterisks indicate significant differences between groups (Mann-Whitney U-test, P < 0.05). ). Asterisks indicate significant differences between groups (Mann-Whitney U-test, P < 0.05).
When chronic hypertension was present, there was more overlapping of PlGF/sFlt-1 ratio concentrations between pregnancies that developed PE and those that did not. Consequently, while the difference in patients without chronic hypertension was significant (P < 0.001), when chronic hypertension was present, it was not significant (P = 0.22). On assessment of NT-proBNP, the overlap was found to be decreased in the presence of chronic hypertension, and differences maintained statistical significance (P < 0.001 for women without chronic hypertension and P = 0.025 for those with chronic hypertension) (Figure 6 ).
DISCUSSION
Although a sFlt-1/PlGF ratio of ≤ 38 has been demonstrated to have a high negative predictive value for ruling out PE 16 , a limitation of this strategy for screening is the high rate of false-positive results. In this cohort, 38.8% (52/134) of pregnancies with a sFlt-1/PlGF ratio > 38 did not exhibit PE at delivery and only 26.9% (36/134) developed this outcome during the following week. Therefore, many attempts have been made to establish sFlt-1/PlGF ratio cut-offs > 38, in order to increase the positive predictive value for PE 12, 15, [45] [46] [47] . On analyzing our data, we identified three sources of false-positive results of sFlt-1/PlGF ratio when predicting PE.
The first source is the time lapse between marker alteration and the indication for pregnancy termination as a result of PE. sFlt-1/PlGF ratio is a long-term marker of poor placentation. Conversely, NT-proBNP is a short-term risk marker and its level increases close to delivery because of PE.
A second source is isolated FGR. A total of 51.4% (18/35) of pregnancies with FGR did not develop PE. The sFlt-1/PlGF ratio rises in severe and early-onset cases of placental dysfunction (FGR with or without PE) 48 . On the contrary, NT-proBNP is not altered in the event of isolated FGR. Consequently, NT-proBNP can help to classify isolated FGR-affected pregnancies, which, in our opinion, is of paramount importance. While there is no curative treatment other than pregnancy termination, neonatal and maternal prognosis depends on when this decision is taken. Pregnancy termination should be decided on the basis of risk assessment, and surveillance of the mother and fetus should define these risks. The surveillance of pregnancy affected by PE should focus on the mother (mainly through laboratory markers), in order to prevent maternal complications. In contrast, in pregnancy affected by isolated FGR, supervision should be focused on the fetus and its wellbeing (mainly through ultrasound markers). Therefore, we did not define PE using the ISSHP 2014 revised statement, which includes new-onset gestational hypertension with FGR without any other maternal features (proteinuria) 49 . The final source of false-positive results identified was chronic hypertension. Endothelial dysfunction, which is the main finding in women with PE 18, 19 , hampers physiological adaptation to hemodynamic changes that occur during pregnancy. In women with chronic hypertension, a lower degree of impaired placentation may be sufficient for PE to develop, as a result of pre-existing endothelial dysfunction in these patients 50 . Accordingly, sFlt-1/PlGF ratio shows a more modest role in predicting superimposed PE 51, 52 . NT-proBNP seems to perform better in this situation, as it is not related to impaired placentation.
Therefore, we compared the strategy of sFlt-1/PlGF ratio using different cut-offs with a strategy combined with NT-proBNP assessment. This study shows that the addition of NT-proBNP assessment yields superior results for the prediction of delivery with PE in the subsequent week compared with the use of sFlt-1/PlGF ratio alone, when the sFlt-1/PlGF ratio is > 38. This therefore suggests that PE is a multisystemic disease from a diagnostic point of view. Furthermore, markers of the maternal manifestation of this placental dysfunction, such as NT-proBNP, might help to differentiate PE from poor placentation affecting only the fetus.
To our knowledge, this is the first study that longitudinally assesses the performance of the combination of these PE markers (sFlt-1/PlGF-ratio and NT-proBNP) in the prediction of the need for pregnancy termination as a result of PE. This is important as, currently, only the first measurement for each patient of the sFlt-1/PlGF ratio is validated for use in PE diagnosis (PROGNOSIS study). Subsequent measurements in the same patient are of unknown value because they cannot be considered as being independent. We decided to use a GEE model as we were interested in population average effects of proposed markers, and this approach requires fewer assumptions than a generalized linear mixed model, which includes subject-specific random effects.
Recently, Verlohren et al. assessed the role of NT-proBNP for predicting PE, and their results were not conclusive 53 . As NT-proBNP is a short-term marker, only longitudinal studies (i.e. those that allow more than one measurement per patient) are capable of defining its role. However, consistent with our findings, high levels of NT-proBNP were related to shorter pregnancy duration in those with PE.
Factors that modify serum NT-proBNP in the non-pregnant population are: heart failure and other heart conditions; previous insulin-dependent diabetes 54 ; increasing age 55 ; race 56 ; and obesity 57 . To date, adjustment in the level of NT-proBNP for these conditions in the pregnant population has not been reported. We did not observe any need for factor adjustment in our cohort.
In our previous study, we observed no early-onset PE when the baseline sFlt-1/PlGF ratio was ≤ 38 in 105 samples taken at between 24 + 0 and 33 + 6 weeks' gestation 32 . This finding is consistent with the PROGNOSIS study post-hoc analysis, which reported a 95% negative predictive value of PE at 4 weeks 58 . Therefore, the value of subsequent measurements of the sFlt-1/PlGF ratio for predicting early-onset PE should be investigated further.
As an initial approximation of the role of these markers in PE, we assessed PE as a unique entity. If a sufficient number of patients are enrolled, we would hope to assess the role of each marker for predicting early-and late-onset PE independently. We encourage researchers to characterize more clearly the maternal manifestations associated with placental dysfunction in order to reduce the FPR of PE prediction.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: 
Table S1
Evaluation of influence of dichotomic factors on N-terminal pro-B natriuretic peptide concentration in pregnancies without pre-eclampsia (n = 52). Only first measurement of each patient is considered
